We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian (VAR) ProBeam Proton Therapy System Now in Thailand
Read MoreHide Full Article
Leading manufacturer of medical devices and software, Varian Medical Systems, Inc. has sealed another international deal for its Proton therapy platform. The company recently announced that Bangkok-based King Chulalongkorn Memorial Hospital has selected its flagship ProBeam Compact single-room proton therapy system, a fully rotational intensity modulated proton therapy platform for cancer treatment in Thailand.
The company plans to initiate treatments using the system by the second half of 2019.
Proton therapy is an advanced form of radiation for cancer patients. A significant addition to Varian’s Particle Therapy business, the latest ProBeam platform features Dynamic Peak scanning technology, robotic patient positioning tools and a suite of motion management tools.
In addition to the equipment, Varian announced plans to provide its Eclipse treatment planning system and ARIA information management system at the hospital. The company is expected to book orders for the equipment by the third quarter of fiscal 2017.
In this regard, second-quarter revenues at the particle therapy segment were up just 1% on a year-over-year basis. We expect this latest development to help Varian improve revenues at this segment.
Of the recent developments at the Proton therapy platform, Varian announced Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) earlier this month. The approval is expected to help Varian fortify its hold in Japan (read more: Varian ProBeam Proton System Gets Okayed by Shonin in Japan).
Share Price & Estimate Revision Trend
Share price of Varian inched up 0.5% to close at $96.75 following the news release.
In fact, the stock has had an impressive run on the bourse over the last three months. The stock has gained 20.1%, much higher than the Zacks classified Medical - Instruments sub-industry’s gain of 5.9%. In fact, the stock’s price level outshined the S&P 500’s addition of 3.6% over the same time frame.
Meanwhile, the company’s recent earnings estimates have been mixed at best. The current quarter has seen one analyst move north in the past two months, compared to three moving south. Meanwhile, full-year estimates have seen two upward revisions, compared to no movement in the opposite direction. This has had a significant impact on the consensus estimate, as the current quarter estimates fell roughly 3% over the last three months, while full-year estimates increased 3.9%.
This somewhat mixed trend justifies the company’s Zacks Rank #3 (Hold).
Bottom Line
Varian has been gaining prominence on its strategic initiatives to bolster its foothold in the niche markets in Asia, courtesy of the Shonin approval in Japan and the latest development in Thailand.
Meanwhile, the Asia proton therapy market is expected to multiply at a CAGR of 18% (Research & Markets). Taking the bountiful prospects into consideration, the latest development should boost investor confidence in the stock.
On the flipside, despite being a leading player in the proton therapy space, cutthroat competition from bigwigs likes Hitachi, Ion Beam Applications and others are expected to increase R&D expenditures for the company, which will keep margins under pressure.
Key Picks
Better-ranked stocks in the broader medical sector include Luminex Corporation , Edwards Lifesciences Corp. (EW - Free Report) and Inogen Inc (INGN - Free Report) . Notably, Inogen and Luminex sport a Zacks Rank #1 (Strong Buy), while Edwards Lifesciences carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen projects a long-term adjusted earnings growth of almost 17.5%. The stock returned 81.7% over the last one year.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 8% over the last three months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.6%. The stock has a solid one-year return of roughly 14.8%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Varian (VAR) ProBeam Proton Therapy System Now in Thailand
Leading manufacturer of medical devices and software, Varian Medical Systems, Inc. has sealed another international deal for its Proton therapy platform. The company recently announced that Bangkok-based King Chulalongkorn Memorial Hospital has selected its flagship ProBeam Compact single-room proton therapy system, a fully rotational intensity modulated proton therapy platform for cancer treatment in Thailand.
The company plans to initiate treatments using the system by the second half of 2019.
Proton therapy is an advanced form of radiation for cancer patients. A significant addition to Varian’s Particle Therapy business, the latest ProBeam platform features Dynamic Peak scanning technology, robotic patient positioning tools and a suite of motion management tools.
In addition to the equipment, Varian announced plans to provide its Eclipse treatment planning system and ARIA information management system at the hospital. The company is expected to book orders for the equipment by the third quarter of fiscal 2017.
In this regard, second-quarter revenues at the particle therapy segment were up just 1% on a year-over-year basis. We expect this latest development to help Varian improve revenues at this segment.
Of the recent developments at the Proton therapy platform, Varian announced Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) earlier this month. The approval is expected to help Varian fortify its hold in Japan (read more: Varian ProBeam Proton System Gets Okayed by Shonin in Japan).
Share Price & Estimate Revision Trend
Share price of Varian inched up 0.5% to close at $96.75 following the news release.
In fact, the stock has had an impressive run on the bourse over the last three months. The stock has gained 20.1%, much higher than the Zacks classified Medical - Instruments sub-industry’s gain of 5.9%. In fact, the stock’s price level outshined the S&P 500’s addition of 3.6% over the same time frame.
Meanwhile, the company’s recent earnings estimates have been mixed at best. The current quarter has seen one analyst move north in the past two months, compared to three moving south. Meanwhile, full-year estimates have seen two upward revisions, compared to no movement in the opposite direction. This has had a significant impact on the consensus estimate, as the current quarter estimates fell roughly 3% over the last three months, while full-year estimates increased 3.9%.
This somewhat mixed trend justifies the company’s Zacks Rank #3 (Hold).
Bottom Line
Varian has been gaining prominence on its strategic initiatives to bolster its foothold in the niche markets in Asia, courtesy of the Shonin approval in Japan and the latest development in Thailand.
Meanwhile, the Asia proton therapy market is expected to multiply at a CAGR of 18% (Research & Markets). Taking the bountiful prospects into consideration, the latest development should boost investor confidence in the stock.
On the flipside, despite being a leading player in the proton therapy space, cutthroat competition from bigwigs likes Hitachi, Ion Beam Applications and others are expected to increase R&D expenditures for the company, which will keep margins under pressure.
Key Picks
Better-ranked stocks in the broader medical sector include Luminex Corporation , Edwards Lifesciences Corp. (EW - Free Report) and Inogen Inc (INGN - Free Report) . Notably, Inogen and Luminex sport a Zacks Rank #1 (Strong Buy), while Edwards Lifesciences carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen projects a long-term adjusted earnings growth of almost 17.5%. The stock returned 81.7% over the last one year.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 8% over the last three months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.6%. The stock has a solid one-year return of roughly 14.8%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>